Gilles Berger

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Venues

Pharmaceutical patent analyst

The Journal of organic chemistry

RSC chemical biology

Proceedings of the National Academy of Sciences of the United States of America

Harvard Medical School

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Harvard Medical School Jan 05 2019

United States

Research Fellow :: Department of Neurosurgery

Université Libre de Bruxelles Feb 01 2017 - Apr 30 2019

Belgium

Postdoctoral Associate :: Pharmaceutical Chemistry

Massachusetts Institute of Technology Jul 01 2015 - Feb 01 2017

United States

Postdoctoral Fellow :: Chemistry

Université de Montréal Jul 01 2014 - Jun 30 2015

Canada

Postdoctoral Associate :: Chemistry

Université Libre de Bruxelles Jan 10 2008 - Jun 30 2014

Belgium

PhD Student - Teaching Assistant :: Pharmaceutical Chemistry

Publications

Charles E Greif, R Tyler Mertens, Gilles Berger, Sean R Parkin, Samuel G Awuah
An anti-glioblastoma gold(i)-NHC complex distorts mitochondrial morphology and bioenergetics to induce tumor growth inhibition. RSC chemical biology 4 (8) (2023)
Aaron Gabriel Nunez Avila, Benoît Deschênes-Simard, Joseph E Arnold, Mathieu Morency, Daniel Chartrand, Thierry Maris, Gilles Berger, Graeme M Day, Stephen Hanessian, James D Wuest
Surprising Chemistry of 6-Azidotetrazolo[5,1- a ]phthalazine: What a Purported Natural Product Reveals about the Polymorphism of Explosives. The Journal of organic chemistry 87 (10) (2022)
Gilles Berger, Erik H Knelson, Jorge L Jimenez-Macias, Michal O Nowicki, Saemi Han, Eleni Panagioti, Patrick H Lizotte, Kwasi Adu-Berchie, Alexander Stafford, Nikolaos Dimitrakakis, Lanlan Zhou, E Antonio Chiocca, David J Mooney, David A Barbie, Sean E Lawler
STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proceedings of the National Academy of Sciences of the United States of America 119 (28) (2022)
Gilles Berger, Anna Wach, Jacinto Sá, Jakub Szlachetko
Reduction Mechanisms of Anticancer Osmium(VI) Complexes Revealed by Atomic Telemetry and Theoretical Calculations. Inorganic chemistry 60 (9) (2021)
Gilles Berger
Pharmaceutical patent landscape for cancer immunotherapy: an interview with Gilles Berger. Pharmaceutical patent analyst 8 (5) (2020)
Sofiane Hocine, Gilles Berger, Stephen Hanessian
Design and Synthesis of Backbone-Fused, Conformationally Constrained Morpholine-Proline Chimeras. The Journal of organic chemistry 85 (6) (2020)
Mickaël Marloye, Sean E Lawler, Gilles Berger
Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy. Pharmaceutical patent analyst 8 (4) (2019)

Gilles Berger.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Gilles Berger